<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">Participants were first vaccinated with influenza, and inoculated with 
 <italic>S. pneumoniae</italic> 3 days later. 117 participants completed the primary study end points and 114 returned their symptom log questionnaires for data analysis (LAIV n = 53, TIV n = 61). As previously described, demographics were similar in both groups 
 <xref rid="b0090" ref-type="bibr">[18]</xref>. 47 participants (41%) became experimentally colonised; 45.3% (n = 24) and 37.7% (n = 23) in the LAIV and TIV groups, respectively. Overall 34.0% (18/53) participants in the LAIV group and 49.2% (30/61) participants in the TIV group reported one or more nasal or non-nasal symptoms, or both, at any time point in the 9 days following vaccination. Statistical difference between these two groups was seen for most nasal symptoms with less symptoms reported in the LAIV group (
 <xref rid="f0005" ref-type="fig">Fig. 1</xref>; 
 <xref rid="f0010" ref-type="fig">Fig. 2</xref> right panel; 
 <xref rid="s0105" ref-type="sec">Suppl Table 2</xref>).
</p>
